Posts

Roche Bets Up to $2.3 Billion on Hanmi’s Muscle-Preserving Obesity Drug

on

Eli Lilly Takes First Legal Action Against Black Market for Experimental Obesity Drug Retatrutide

on

Roche shelves Carmot obesity asset, reins in AI token use in R&D

on

Lilly's triple-G drug helps patients lose roughly a quarter of weight, showcasing competitive profile

on

Boehringer Ingelheim and Zealand Pharma's Survodutide Matches Wegovy in Weight Loss but Trails Zepbound in Phase 3 Trial

on

FDA Approves Eli Lilly's Oral GLP-1 Pill Foundayo (Orforglipron) as Response to Novo Nordisk

on

Novo Nordisk's High-Dose Wegovy Receives FDA Approval Under Commissioner's Voucher Program

on

China Approves Pfizer's GLP-1 Obesity Drug Xianweiying Shortly After Licensing Deal with Sciwind

on

Zealand Pharma and Roche's Obesity Drug Development and Clinical Progress

on

Novo Nordisk's Next-Gen Obesity Drug Outperforms Wegovy in Phase III Blood Sugar Control

on

Roche's CT-388 Obesity Drug Achieves 22.5% Weight Loss in Phase II, Advances to Phase III

on

Novo Nordisk's Wegovy Pill Launches Strongly Amid Analyst Caution

on

Corxel Pharmaceuticals Raises $287M Series D1 to Advance Oral GLP-1 Obesity Drug CX11

on

Roche's Patent License Deal with Structure Therapeutics for CT-996 Obesity Drug

on

Lilly Slightly Lowers Self-Pay Prices for Single-Dose Vials of Zepbound

on